Comparisons Of Inflammatory Biomarkers And Cardiovascular Risk Scores Before And After Conversion To Full Dose Myfortic Using Two Hour Neoral Monitoring.

Trial Profile

Comparisons Of Inflammatory Biomarkers And Cardiovascular Risk Scores Before And After Conversion To Full Dose Myfortic Using Two Hour Neoral Monitoring.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Ciclosporin (Primary) ; Mycophenolate sodium (Primary) ; Mycophenolate mofetil; Prednisone
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms COBACAM
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Oct 2015.
    • 05 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Oct 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top